Indeed, TPL2 kinase inhibitors demonstrate therapeutic potential in multiple in vivo models of inflammatory diseases including RA, MS, immune thrombocytopenic purpura and inflammatory bowel disease [59]. Here, MAP3K8 is linked to inflammatory bowel disease.